PFE vs RCKT
PFE: Global biopharmaceutical company discovering, developing, and manufacturing prescription medicines and vaccines across oncology, immunology, cardiovascular, and infectious disease. RCKT: Rocket Pharmaceuticals is a clinical-stage biotechnology company developing transformative gene therapies for rare, high-unmet-need genetic disorders.
Side-by-side fundamentals
| Metric | PFE | RCKT | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $24.82 | $3.30 | |
| Market cap as of 2026-07-23 | $142.0B | $368M | |
| P/E as of 2026-07-23 | 18.96 | n/a | |
| PEG as of 2026-07-23 | -3.38 | n/a | |
| Net margin as of 2026-07-23 | +11.8% | n/a | |
| Gross margin as of 2026-07-23 | +74.8% | n/a | |
| Operating margin as of 2026-07-23 | +15.4% | n/a | |
| ROE as of 2026-07-23 | +8.4% | -70.8% | PFE higher |
| ROA as of 2026-07-23 | +3.6% | -59.6% | PFE higher |
| Debt / equity as of 2026-07-23 | 0.72 | 0.09 | RCKT lower |
| Revenue growth (YoY) as of 2026-07-23 | +1.4% | n/a | |
| Revenue CAGR (3y) SEC XBRL | -14.8% | n/a | |
| Dividend yield as of 2026-07-23 | +6.9% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-07-23 | 0.28 | 0.46 | |
| 1-year return as of 2026-07-22 close | -1.3% | -2.1% | PFE higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.